Bariatric surgery for obesity and metabolic conditions in adults.

This review summarizes recent evidence related to the safety, efficacy, and metabolic outcomes of bariatric surgery to guide clinical decision making. Several short term randomized controlled trials have demonstrated the effectiveness of bariatric procedures for inducing weight loss and initial remission of type 2 diabetes. Observational studies have linked bariatric procedures with long term improvements in body weight, type 2 diabetes, survival, cardiovascular events, incident cancer, and quality of life. Perioperative mortality for the average patient is low but varies greatly across subgroups. The incidence of major complications after surgery also varies widely, and emerging data show that some procedures are associated with a greater risk of substance misuse disorders, suicide, and nutritional deficiencies. More research is needed to enable long term outcomes to be compared across various procedures and subpopulations, and to identify those most likely to benefit from surgical intervention. Given uncertainties about the balance between the risks and benefits of bariatric surgery in the long term, the decision to undergo surgery should be based on a high quality shared decision making process. © BMJ Publishing Group Ltd 2014.

Introduction

Although the global pandemic of obesity has continued unabated over the past two decades, little progress has been made in its behavioral and drug treatment, especially in patients with severe obesity. By contrast, the evidence base for bariatric surgical procedures has expanded rapidly over this time, and it has yielded important short term and long term data on the efficacy and safety of surgical treatment for obesity and related metabolic disorders. Because trade-offs between the potential risks and benefits of bariatric surgical procedures exist, this review of the evidence for bariatric surgery aims to guide adult patients and their clinicians through a well informed, shared decision making process.

Prevalence

Nationally representative estimates from 2009 to 2010 indicate that 35.5% of the adult population in the United States is obese (defined as a body mass index (BMI) ≥30).1 About 15.5% of the US adult population has a BMI of 35 or more and 6.3% are severely obese (BMI ≥40).1

Data on the prevalence of severe obesity in other countries is scant, but the health survey of England showed that 1.7% of men and 3.1% of women had a BMI of 40 or more in 2012.2 In Sweden in 2005, 1.3% of men had a BMI of 35 or more,3 and in Australia in 2006, 8.1% of adults had a BMI of 35 or more.4

The total number of bariatric procedures worldwide was estimated at 340 768 in 2011.5 The most commonly performed procedures were Roux-en-Y gastric bypass (46.6%), vertical sleeve gastrectomy (27.8%), adjustable gastric banding (17.8%), and biliopancreatic diversion with duodenal switch (2.2%).5 The largest number of operations were performed in the US and Canada together (101 645), followed by Brazil (65 000), France (27 648), Mexico (19 000), Australia and New Zealand (12 000), and the United Kingdom (10 000). No other nation performed 10 000 or more operations in 2011.5

Sources and selection criteria

We based this review on articles found by searching Medline, the Cochrane Collaboration Library, and Clinical Evidence from their inception until September 2013 with the terms “bariatric surgery”, “gastric bypass”, “gastric banding”, “sleeve gastrectomy”, and “biliopancreatic diversion”. Our search was limited to English language articles. Priority was given to evidence obtained from systematic literature reviews, meta-analyses, and randomized controlled trials when possible.

Obesity related complications

Severe obesity (most often defined as a BMI ≥35 with comorbid health conditions or a BMI ≥40 without such conditions) is a highly prevalent chronic disease,1 which leads to substantial morbidity,6 premature mortality,7 impaired quality of life,8 and excess healthcare expenditures.9 Severely obese adults are disproportionately affected by chronic health conditions, such as type 2 diabetes (28% of severely obese adults),10 major depression (7%),11 coronary heart disease (14-19%),6 and osteoarthritis (10-17%).6

Treatment options

Treatments for severe obesity include lifestyle interventions, pharmacotherapy, and bariatric surgical procedures. Evidence from decades of weight loss research indicates that lifestyle interventions and pharmacotherapy often fail to help severely obese people lose enough weight to improve their health and quality of life in the long term.12 13 14 However, a growing body of evidence indicates that bariatric surgery can induce sustained reductions in weight, improve comorbidities, and prolong survival.15 16 17 18 19 20 21 22 23 24

Bariatric procedures were first developed more than 50 years ago. However, in the past 20 years, a dramatic increase in the prevalence of severe obesity combined with improvements in the efficacy and safety of bariatric surgical techniques has led to a 20-fold increase in the number of procedures performed annually in the US.25 Recent improvements in bariatric safety outcomes have been linked to an increase in the volume of cases performed, a shift to the laparoscopic technique, and an increase in the use of the lower risk adjustable gastric banding procedure.26 Current US guidelines recommend consideration of bariatric surgery for people who have not responded to non-surgical treatments if they have a BMI of at least 40 or at least 35 if they also have serious diseases related to obesity.27

Types of bariatric surgery procedures and mechanisms of weight loss

Bariatric surgical procedures have evolved dramatically over the past 50 years (fig 1 ). Modern procedures are most often described in anatomic terms according to their presumed mechanical effect, using phrases like “gastric restrictive” or “intestinal bypass” for ease of understanding, but recent basic science investigations may soon change this characterization to one based on physiology. In addition, since the 1990s the standard surgical technique has shifted from an open incisional approach to a minimally invasive or laparoscopic approach, almost exclusively.28

Fig 1 The evolution of bariatric surgery procedures. Use the interactive tool at:http://www.bmj.com/content/349/bmj.g3961/infographic

The first bariatric procedure in wide use was known as the jejunoileal bypass, and it involved an intestinal bypass in which the proximal jejunum was bypassed into the distal ileum. This resulted in extreme weight loss by way of profound malabsorption and was eventually abandoned some years later after many patients developed severe protein-energy malnutrition.29

The next major bariatric procedures to be introduced were the horizontal gastroplasty and the vertical banded gastroplasty, which were thought to be purely restrictive procedures made possible through the development of surgical stapling devices. In a horizontal gastroplasty, a pouch was created in the upper stomach by introducing a horizontal suture line with several staples removed (the stoma) to allow for the passage of food (fig 2A ). With vertical banded gastroplasty, a vertical staple line was created parallel to the lesser curvature of the stomach and the outlet or stoma was reinforced with a mesh collar to prevent enlargement (fig 2B). Both procedures have now been abandoned owing to the introduction of newer more effective laparoscopic procedures, and because the stomach staple line often separated or the stoma tended to enlarge, leading to weight regain or severe gastroesophageal reflux, or both.30 31

Fig 2 (A) Horizontal gastroplasty; (B) vertical banded gastroplasty; (C) Roux-en-Y gastric bypass; (D) transected Roux-en-Y gastric bypass; (E) laparoscopic adjustable gastric band; (F) biliopancreatic diversion; (G) biliopancreatic diversion with duodenal switch; (H) vertical sleeve gastrectomy

The gastric bypass was originally introduced in 1969 by Mason and Ito,32 and it was later modified into a Roux-en-Y gastric bypass configuration for drainage of the proximal gastric pouch to avoid bile reflux (fig 2C).33 Over time, the Roux-en-Y gastric bypass has been refined into its current laparoscopic form. This includes a small proximal gastric pouch of 15-20 mL, a measured and smaller gastric-to-intestinal stoma size (with or without cuff restriction), and a complete staple line transection to avoid staple line separation or failure (fig 2D).34

The next major procedure to be introduced was the adjustable form of gastric banding, which has been modified for laparoscopic placement and creates a small superior gastric pouch with an adjustable outlet (fig 2E).35 36 The adjustable gastric band is a silicone belt with an inflatable balloon in the lining that is buckled into a closed ring around the upper stomach. A reservoir port is placed under the skin for adjustments to the stoma size.

Two procedures that use a more extreme intestinal bypass along with some modest gastric reduction are the biliopancreatic diversion and the biliopancreatic diversion with duodenal switch operations, which are most often used for “super” obese patients (usually BMI ≥50).37 38 39 Biliopancreatic diversion combines a subtotal (2/3rds) distal gastrectomy and a very long Roux-en-Y anastomosis with a short common intestinal channel for nutrient absorption (fig 2F). Biliopancreatic diversion with duodenal switch combines a 70% greater curve gastrectomy with a long intestinal bypass, where the duodenal stump is defunctionalized or “switched” to a gastroileal anastomosis (fig 2G).

Finally, the most recent major bariatric procedure to be introduced is the vertical sleeve gastrectomy, and it is rapidly increasing in popularity.40 This technique consists of a 70% vertical gastric resection, which creates a long and narrow tubular gastric reservoir with no intestinal bypass component (fig 2H).

Despite the basic “restrictive” and “intestinal bypass” anatomic conceptualizations of bariatric surgical procedures, there is much research ongoing in animal and human models towards understanding their underlying mechanisms of action. These actions may be more physiological (altered gastrointestinal signals) than nutrient restrictive and are likely to be both endocrine and neuronal in nature.41

Some of the potential candidates for the mechanisms of action of bariatric procedures include alterations in ghrelin, leptin, glucagon-like peptide-1, cholecystokinin, peptide YY, gut microbiota, and bile acids.42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 It may be necessary in the future to group bariatric procedures not on the basis of anatomic surgical similarities but on how they affect key physiological variables, which would provide greater mechanistic insight into how the procedures work.41

Below we summarize key findings from randomized trials and major long term observational studies that compare bariatric procedures with non-surgical management of obesity. Table 1 provides an overview of the results of these studies in terms of weight change, remission from and incidence of type 2 diabetes, as well as long term survival.

Table 1

Effectiveness of bariatric surgery compared with non-surgical management*

Study	Study details	Weight change	T2DM remission	T2DM incidence	Mortality and survival
Meta-analysis21	Meta-analysis of 11 RCTs (n=796); cohorts include RYGB, AGB, BPD, VSG v non-surgical treatments	Bariatric surgery treatment: 1-2 year weight change, mean difference −26 kg, 95% CI −31 to −21; P<0.001 v non-surgical treatment	Bariatric surgery treatment: complete case analysis relative risk 22.1, 3.2 to 154.3; P=0.002; conservative analysis 5.3, 1.8 to 15.8; P=0.003 v non-surgical treatment	Not reported	No cardiovascular events or deaths reported after bariatric surgery or in control populations
Swedish Obese Subjects study18 24	Prospective observational with matched controls (n=2010; 68% VBG, 19% banding, 13 % RYGB); 2037 matched controls	Bariatric surgery treatment: 2, 10, 15, 20 year weight change mean −23%, −17%, −16%, and −18%, respectively; matched control treatment: 2, 10, 15, 20 year weight loss mean 0%, 1%, −1%, and −1%, respectively	Bariatric surgery treatment: 2 years 72% remission (odds ratio for remission: 8.4, 5.7 to 12.5; P<0.001); 10 years 36% durable remission (3.5, 1.6 to 7.3; P<0.001)	Bariatric surgery treatment: 2, 10, and 15 years, reduced risk of developing T2DM by 96%, 84%, and 78%, respectively, in people without the condition at baseline	Bariatric surgery treatment: 16 years, 29% lower risk of death from any cause (hazard ratio 0.71, 0.54 to 0.92; P=0.01) v usual care; common causes of death: cancer and myocardial infarction
Utah Mortality study17	Retrospective observational with matched controls (7925 RYGB; 7925 weight matched controls)	Not reported	Not reported	Not reported	Bariatric surgery treatment: average 7.1 years post-treatment, 40% (hazard ratio 0.60, 0.45 to 0.67; P<0.001), 49% (0.51, 0.36 to 0.73; P<0.001), and 92% (0.08, 0.01 to 0.47; P=0.005) reduction in all cause mortality, cardiovascular mortality, and T2DM mortality, respectively
Utah Obesity study67	Prospective observational with matched controls; 418 RYGB; 417 bariatric surgery seekers who did not undergo surgery (control 1); 321 population based severely obese matched controls (control 2)	6 year weight change: −27.7%, +0.2%, and 0% of initial body weight for bariatric surgery, control 1, and control 2, respectively	6 year remission: 62%, 8%, and 6% for bariatric surgery, control 1, and control 2, respectively	6 year incident T2DM: 2%, 17%, and 15% for bariatric surgery, control 1, and control 2, respectively	Deaths at 6 years: 12 (2.8%), 14 (3.3%), and 3 (0.93%) for bariatric surgery, control 1, and control 2, respectively

* AGB=adjustable gastric banding; BPD=biliopancreatic diversion; LABS=Longitudinal Assessment of Bariatric Surgery study; RCT=randomized controlled trial; RYGB=Roux-en-Y gastric bypass; T2DM=type 2 diabetes; VBG=vertical banded gastroplasty; VSG=vertical sleeve gastrectomy.

Randomized controlled trials

A recent systematic review and meta-analysis summarized all randomized controlled trials (RCTs) that have compared bariatric surgery with non-surgical treatments for obesity.21 The review analysed 11 trials comprising 796 people with a BMI of 30-52. These studies generally focused on cohorts with type 2 diabetes with one to two years of follow-up. They provided good evidence of the effectiveness of bariatric procedures, including Roux-en-Y gastric bypass,60 61 62 adjustable gastric banding,63 64 biliopancreatic diversion,61 and vertical sleeve gastrectomy.62 These procedures resulted in greater short term (1-2 years) weight loss (mean difference −26 kg; 95% confidence interval −31 to −21; P<0.001) and greater remission of type 2 diabetes (complete case analysis relative risk of remission: 22.1, 3.2 to 154.3; P=0.002; conservative analysis: 5.3, 1.8 to 15.8; P=0.003) compared with various non-surgical treatments.60 61 62 63 64 Recently, two additional small RCTs have been published that show similar short term results for both weight loss and type 2 diabetes.65 66

In addition, serum triglycerides and high density lipoproteins were significantly reduced by bariatric procedures, but blood pressure and other lipoproteins were not (although some studies showed reduced use of drugs for these conditions).21 The review also noted a lack of evidence from RCTs beyond two years with respect to mortality, cardiovascular diseases, and adverse events.

Another recent systematic review focused on weight loss and glycemic control in class I obese (BMI 30-34.9) adults with type 2 diabetes and identified three RCTs with results similar to those seen in class II (BMI 35-39.9) and severely obese populations. However, the review also noted a lack of long term studies.22

Swedish Obese Subjects study

Given the absence of long term RCTs comparing bariatric procedures with non-surgical treatment of obesity, we must turn to large observational cohort studies to answer important questions about long term outcomes.18 24 67 68 Much of our current knowledge about the long term results of bariatric surgery come from the Swedish Obese Subjects (SOS) study. This study started in 1987 as a prospective trial of 2010 people undergoing bariatric surgery compared with 2037 usual care controls who were matched on 18 clinical and demographic variables.24

The most common bariatric procedure performed in SOS was the vertical banded gastroplasty (68%), followed by gastric banding (19%), and Roux-en-Y gastric bypass (13%). Follow-up rates are reported at 99% for some endpoints (including mortality), but physical and laboratory follow-up rates are lower, with imputation techniques used for sensitivity analysis.24 The SOS investigators have published widely on health outcomes beyond 10 years, including weight loss, mortality, remission from and incidence of type 2 diabetes, cardiovascular events, incident cancer, psychosocial outcomes, and healthcare use and costs.18 24 68 69 70 71 72

Weight loss among surgical patients in SOS was greater than in controls (mean changes in body weight at 2, 10, 15, and 20 years were −23%, −17%, −16%, and −18% in the surgery group and 0%, 1%, −1%, and −1% in the control group, respectively).24 After 15 years, the mean weight loss by procedure type was 27% (standard deviation 12%) for Roux-en-Y gastric bypass, 18% (11%) for vertical banded gastroplasty, and 13% (14%) for gastric banding.24

The SOS study also showed major improvements in obesity related comorbidities. In the surgical group there was a 72% remission of type 2 diabetes after two years (odds ratio for remission 8.4, 5.7 to 12.5; P<0.001) and 36% durable remission after 10 years (3.5, 1.6 to 7.3; P<0.001).69

In spite of the considerable recurrence of type 2 diabetes over time, bariatric surgery was associated with a lower incidence of myocardial infarction (hazard ratio 0.56, 0.34 to 0.93; P=0.025) and other complications of type 2 diabetes.68 73 Recently the SOS study showed that bariatric surgery also reduced the risk of developing type 2 diabetes by 96%, 84%, and 78% after two, 10, and 15 years in people without the condition at baseline.74 This study also found that bariatric surgery was associated with a reduced incidence of fatal or non-fatal cancer in women but not in men (hazard ratio in women 0.58, 0.44 to 0.77; P<0.001; in men 0.97, 0.62 to 1.52; P=0.90).71 Finally, at 16 years’ follow-up, surgery was associated with a 29% lower risk of death from any cause (0.71, 0.54 to 0.92; P=0.01) compared with usual care.18

Utah obesity studies

Another important long term observational study performed in Utah from 1984 to 2002 comprised 7925 people who had undergone Roux-en-Y gastric bypass and 7925 weight, age, and sex matched controls. This study showed a 40% reduction in all cause mortality (hazard ratio 0.60, 0.45 to 0.67; P<0.001) and a 49% (0.51, 0.36 to 0.73; P<0.001) and 92% (0.08, 0.01 to 0.47; P=0.005) reduction in death from cardiovascular disease and death related to type 2 diabetes, respectively, at an average of 7.1 years later.17

Two other large retrospective observational studies support the findings from the SOS and Utah studies that bariatric surgery is associated with lower mortality than usual care.75 76 However, another retrospective observational study of US veterans found no significant association between bariatric surgery and survival compared with usual care at a mean 6.7 years of follow-up.77 The discrepant findings of this last study are probably a result of its focus on a high risk population as well as insufficient power and duration of follow-up.

A separate ongoing prospective Utah Obesity Study looked at more than 400 people who had undergone Roux-en-Y gastric bypass surgery and two non-randomized matched control groups—each with about 400 severely obese subjects. One control group comprised people who had sought surgery but did not undergo the operation; the other was a population based group. The study found that those in the surgery group lost 27.7% of their initial body weight compared with 0.2% weight gain in the surgery seekers and 0% change in the population based group at six years.67 Diabetes was in remission in 62% of Roux-en-Y gastric bypass group and in only 8% and 6% of the control groups. Incident type 2 diabetes was noted in 2% of the Roux-en-Y gastric bypass group and in 17% and 15% of the control groups at six years.67

The LABS-2 study

The Longitudinal Assessment of Bariatric Surgery (LABS-2) study deserves mention, despite not including a non-surgical control group, because it is the largest ongoing prospective multicenter observational bariatric cohort study. LABS-2 will assess weight change and comorbid conditions in 2458 participants (1738 Roux-en-Y gastric bypass surgery, 610 adjustable gastric banding, and 110 other procedures) recruited between 2005 and 2009 who have been followed for three years to date.78 In the LABS-2 cohort, median weight change was 31.5% for Roux-en-Y gastric bypass and 15.9% for adjustable gastric banding after three years, with much variability in response to each surgical treatment. Remission of type 2 diabetes was noted in 67% and 28% of those who had undergone Roux-en-Y gastric bypass and adjustable gastric banding, respectively. The incidence of type 2 diabetes was 0.9% and 3.2%, respectively, over the three years.78

Long term studies of quality of life

Few long term studies have assessed the impact of bariatric surgery on quality of life. However, three studies of six to 10 years’ duration suggest that bariatric procedures are associated with greater improvements in generic and obesity specific measures of quality of life than non-surgical care.72 79 80 Physical functioning domains seem to be more responsive to bariatric procedures than mental health domains, although more research is needed, especially in patients with class I obesity.

Effectiveness of bariatric surgery—comparisons between procedures

In the past 10 years, many systematic reviews of bariatric surgery have attempted to summarize and quantify differences in the efficacy and safety of various procedures.15 16 19 20 23 81 82 83 84 85 86 A major challenge in summarizing this literature is the fact that no single randomized trial has included all of the most common procedures (Roux-en-Y gastric bypass, adjustable gastric banding, vertical sleeve gastrectomy, and biliopancreatic diversion with duodenal switch). Therefore, inference must be made through pooled analysis of data from many disparate randomized and non-randomized studies of bariatric surgery. In addition, no studies have examined differences in long term survival, incident cardiovascular events, and quality of life across procedures.

One of the most comprehensive systematic reviews analysed 136 studies and 22 094 patients undergoing bariatric surgery.16 However, only five of the included studies were randomized trials (28 non-RCTs and 101 uncontrolled case series), and the review did not include data on vertical sleeve gastrectomy. The review found a strong trend towards different weight loss outcomes across procedures. Weighted mean percentage of excess weight loss (%EWL) was 50% (32% to 70%) for adjustable gastric banding, 68% (33% to 77%) for Roux-en-Y gastric bypass, 69% (48% to 93%) for vertical banded gastroplasty, and 72% (62% to 75%) for biliopancreatic diversion with duodenal switch. The rate of type 2 diabetes remission also varied greatly across procedures. The rate was 48% (29% to 67%) for adjustable gastric banding, 84% (77% to 90%) for Roux-en-Y gastric bypass, 72% (55% to 88%) for vertical banded gastroplasty, and 99% (97% to 100%) for biliopancreatic diversion with duodenal switch. A similar pattern of disease remission was seen for hypertension, dyslipidemia, and obstructive sleep apnea, with the highest rates of remission seen in patients who had undergone biliopancreatic diversion with duodenal switch, followed by Roux-en-Y gastric bypass, vertical banded gastroplasty, and lastly adjustable gastric banding.16

There is an ongoing debate about the comparative effectiveness of two of the most common procedures—adjustable gastric banding and Roux-en-Y gastric bypass—for weight loss and improvement in comorbidity. Consistent with the systematic review presented above, several other systematic reviews have concluded that Roux-en-Y gastric bypass is more effective for weight loss than adjustable gastric banding.16 81 82 83 However, there have been only two small head to head RCTs (with follow-up at four and five years).87 88

Insufficient data are available from RCTs to examine differences between adjustable gastric banding and Roux-en-Y gastric bypass in improvements in comorbidity. However, systematic reviews of non-randomized studies indicate greater remission of type 2 diabetes, hypertension, dyslipidemia, and sleep apnea with Roux-en-Y gastric bypass versus adjustable gastric banding.16 81 By contrast, one systematic review of 19 long term observational studies (≥10 years’ duration; no RCTs) found a mean %EWL of 54.2% for adjustable gastric banding versus 54.0% for Roux-en-Y gastric bypass.23 These discrepant data suggest that some very experienced, high volume surgical centers with rigorous programs for long term post-surgical care and follow-up may achieve weight loss results with adjustable gastric banding similar to those achieved with Roux-en-Y gastric bypass. However, data from these types of centers are not often seen in the surgical literature, and more research is needed to identify the optimal requirements of an adjustable gastric banding program.

Two recent systematic reviews compared the outcomes of vertical sleeve gastrectomy with other procedures.85 86 One review identified 15 RCTs with 1191 patients.85 The %EWL ranged from 49% to 81% for vertical sleeve gastrectomy, from 62% to 94% for Roux-en-Y gastric bypass, and from 29% to 48% for adjustable gastric banding, with follow-up ranging from six months to three years. The type 2 diabetes remission rate ranged from 27% to 75% for vertical sleeve gastrectomy versus 42% to 93% for Roux-en-Y gastric bypass.85

The second review compared only vertical sleeve gastrectomy and Roux-en-Y gastric bypass. It identified six RCTs and two non-randomized controlled studies with follow-up ranging from three months to two years.86 It found significantly greater improvements in BMI with Roux-en-Y gastric bypass than with vertical sleeve gastrectomy (mean difference in BMI 1.8, 0.5 to 3.2). It also found greater improvements in total cholesterol, high density lipoprotein-cholesterol, and insulin resistance with Roux-en-Y gastric bypass versus vertical sleeve gastrectomy.86 Longer term comparative effectiveness data on vertical sleeve gastrectomy are clearly needed. However, the effect of vertical sleeve gastrectomy on weight loss and comorbidity improvements seems to be somewhere between those of Roux-en-Y gastric bypass and adjustable gastric banding.89

Complications of bariatric surgery

Bariatric surgery is not without risks. Perioperative mortality for the average patient is low (<0.3%) and declining,88 but it varies greatly across subgroups, with perioperative mortality rates of 2.0% or higher in some patient populations.90 91 92 93 The incidence of complications in the first 30-180 days after surgery varies widely from 4% to 25% and depends on the definition of complication used, the type of bariatric procedure performed, the duration of follow-up, and individual patient characteristics.15 26 91 94 95

Findings from major studies

Among the 11 RCTs (796 patients) that have compared bariatric surgery with non-surgical care, rates of adverse events were higher in patients having surgery, but follow-up was limited to two years.21 No cardiovascular events or deaths were seen in either group, but the most common adverse events after surgery were iron deficiency anemia (15% with intestinal bypass operations) and reoperations (8%).21 These RCTs were not large enough to compare safety across procedure types, and most of the comparative data on complications come from larger observational studies.

The first phase of the Longitudinal Assessment of Bariatric Surgery (LABS-1) study prospectively assessed 30 day complications in 4776 severely obese patients who underwent a first bariatric surgical procedure (25% adjustable gastric banding, 62% laparoscopic Roux-en-Y gastric bypass, 9% open Roux-en-Y gastric bypass, and 3% another procedure) between 2005 and 2007.91 The 30 day mortality rate was 0.3% for all procedures, with a major adverse outcome rate (predefined composite endpoint that included death, venous thromboembolism, reintervention (percutaneous, endoscopic, or operative), or failure to be discharged from the hospital in 30 days) of 4.1%. Major predictors of an increased risk of complications were a history of venous thromboembolism, a diagnosis of obstructive sleep apnea, impaired functional status (inability to walk 61 m; 1 m=3.28 ft), extreme BMI (≥60), and undergoing Roux-en-Y gastric bypass by the open technique.91

Other large observational studies, such as SOS, have shown higher rates of complications, with 14.5% having at least one non-fatal complication over the first 90 days, including (in order of frequency) pulmonary complications, vomiting, wound infection, hemorrhage, and anastomotic leak.24 However, the SOS included mostly open and vertical banded gastroplasty procedures, which are rarely performed today. Nonetheless, the 90 day mortality rate in SOS was low at 0.25%.

A meta-analysis of 361 studies (97.7% non-randomized observational design) of 85 048 patients reported important differences in mortality up to 30 days across different laparoscopic bariatric procedures. It found 0.06% (0.01% to 0.11%) for adjustable gastric banding, 0.21% (0.00% to 0.48%) for vertical banded gastroplasty, 0.16% (0.09% to 0.23%) for Roux-en-Y gastric bypass, and 1.11% (0.00% to 2.70%) for biliopancreatic diversion with duodenal switch.90 The review also found significantly higher mortality with open procedures than with laparoscopic procedures.90 A clinically useful prognostic risk score has been developed and validated in 9382 patients to predict 90 day mortality after Roux-en-Y gastric bypass surgery using five clinical characteristics: BMI 50 or more, male sex, hypertension, known risk factor for pulmonary embolism, and age 45 years or more.96 97 Patients with four to five of these characteristics are at higher risk of death (4.3%) by 90 days than those with none or one of these characteristics (0.26%).98

A systematic review of 15 RCTs of vertical sleeve gastrectomy found no deaths in 795 patients but a 9.2% mean complication rate (range 0-18%).85 In the American College of Surgeons Bariatric Surgery Network database, mortality 30 days after vertical sleeve gastrectomy was 0.11%, between that for adjustable gastric banding (0.05%) and Roux-en-Y gastric bypass (0.14%).89 The 30 day complication (morbidity) rate was 5.6% for vertical sleeve gastrectomy, 1.4% for adjustable gastric banding, and 5.9% for Roux-en-Y gastric bypass.

Reoperation

A worrying trend is the relatively frequent rate of reoperation as a result of complications or insufficient weight loss (or both), especially for adjustable gastric banding. In a prospective cohort of 3227 patients who had undergone this procedure, 1116 (35%) patients underwent revisional procedures. These were performed because of proximal enlargement (26%), port and tubing problems (21%), and erosion (3.4%), with no acute band slippages specifically noted. The need for revision because of proximal enlargement of the gastric pouch decreased dramatically over 17 years as the surgical technique evolved, from 40% to 6.4%, and no acute slippages were specifically noted; however, the band was ultimately removed in 5.6% of all people.23

Other long term cohorts suggest that adjustable gastric banding removal rates may be as high as 50%.99 100 In the LABS-2 cohort study, the rate of revision or reoperation was higher for adjustable gastric banding than for Roux-en-Y gastric bypass at three years of follow-up.101 However, one systematic review of long term studies indicates that the rate of revisional surgery for Roux-en-Y gastric bypass is similar to that for adjustable gastric banding (22% for Roux-en-Y gastric bypass, range 8-38%; 26% for adjustable gastric banding, 8-60%).23 Many revisions are probably due to weight regain or failure to lose enough weight, but the specific cause for revision is often not indicated. The higher rates of reoperation with adjustable gastric banding may simply reflect the reversible nature of that surgical procedure compared with other relatively permanent procedures. Overall, more long term data are needed for all procedure types to categorize and understand the cause, nature, and severity of these complications.102

Psychosocial risks

Emerging data from observational studies suggest that some bariatric procedures introduce a greater long term risk of substance misuse disorders,103 104 105 suicide,106 and nutritional deficiencies.107 Pharmacokinetic studies indicate that the gastrointestinal anatomy after Roux-en-Y gastric bypass and vertical sleeve gastrectomy leads to more rapid absorption of alcohol and marked increases in blood alcohol concentrations per dose. This may inadvertently increase the frequency of physiological binges and subsequent alcohol misuse disorder.108 109 110

In the SOS study, Roux-en-Y gastric bypass was associated with increased alcohol consumption and an increase in alcohol misuse events (hazard ratio 4.9) over 20 years, but more than 90% of patients remained below the World Health Organization cut off for low risk alcohol consumption.105 Similarly, in the LABS-2 study, alcohol misuse disorders were more common in the second postoperative year (9.6%) in those undergoing Roux-en-Y gastric bypass than at baseline (7.6%).103

The risk of suicide may be increased after bariatric surgery, although the cause is unclear. The Utah Mortality study showed a 58% increase in all non-disease causes of death in the Roux-en-Y gastric bypass group compared with the matched control population, including a small but significant increase in suicides, accidental deaths, and poisonings.17 Similar findings were observed in the second Utah Obesity Study,67 and another observational study found that suicide rates in post-bariatric surgery patients were significantly higher than age and sex matched rates in the US.111 Given the paucity of data on preoperative psychological risk assessment and long term follow-up after bariatric surgery, rigorous research is needed to inform future practice guidelines and care standards in this area.

Nutritional deficiencies

Finally, evidence indicates that vitamin and mineral deficiencies, including deficiencies of calcium, vitamin D, iron, zinc, and copper, are common after bariatric surgery.107 Guidelines suggest screening patients for iron, vitamin B12, folic acid, and vitamin D deficiencies preoperatively. Patients should also be given daily nutritional supplementation postoperatively, including two adult multivitamin plus mineral supplements (each containing iron, folic acid, and thiamine), 1200 to 1500 mg of elemental calcium, at least 3000 IU of vitamin D, and vitamin B12 as needed. In addition, they should receive annual screening for specific deficiencies, including vitamin B12 (table 2).112 Insufficient evidence is available on optimal dietary and nutritional management after bariatric surgery, including how to manage some of the complications of surgery (such as chronic nausea and vomiting, hypoglycemia, anastomotic ulcers and strictures, and failed weight loss).

Table 2

Recommended postoperative nutritional monitoring* 112

Recommendation	AGB	VSG	RYGB	BPD-DS
Bone density (DXA) at 2 years	Yes	Yes	Yes	Yes
24 hour urinary calcium excretion at 6 months and annually	Yes	Yes	Yes	Yes
Vitamin B12 annually (methylmalonic acid and homocysteine optional) then every 3-6 months if supplemented	Yes	Yes	Yes	Yes
Folic acid (red blood cell folic acid optional), iron studies, vitamin D, intact parathyroid hormone	No	No	Yes	Yes
Vitamin A initially and every 6-12 months thereafter	No	No	Optional	Yes
Copper, zinc, and selenium evaluation with specific findings	No	No	Yes	Yes
Thiamine evaluation with specific findings	Yes	Yes	Yes	Yes

*AGB=adjustable gastric banding; BPD-DS=biliopancreatic diversion with duodenal switch; DXA=dual energy X ray absorptiometry; RYGB=Roux-en-Y gastric bypass; VSG=vertical sleeve gastrectomy.

Guideline supported indications for bariatric surgery and their limitations

The first guidelines for patient selection in bariatric surgery were established in 1991 at a National Institutes of Health (NIH) consensus conference and were based on the limited literature available at that time.113 The initial selection criteria were a BMI of 40 or more, or a BMI of 35.0-39.9 with one or more obesity related comorbidity. In 2004, a Medicare Coverage Advisory Committee concluded that there was enough scientific evidence to support the coverage of open and laparoscopic bariatric surgery for patients who met the NIH criteria, and many private insurers and state Medicaid programs in the US soon followed suit.114

Currently, the Centers for Medicare and Medicaid Services (CMS) covers open and laparoscopic Roux-en-Y gastric bypass, laparoscopic adjustable gastric banding, and open and laparoscopic biliopancreatic diversion with duodenal switch for Medicare beneficiaries.115 In addition, in 2012 the CMS determined that local Medicare administrative contractors may individually determine coverage of laparoscopic vertical sleeve gastrectomy. In 2009, the CMS added a requirement that, for surgery to be reimbursed, it must be performed in “centers of excellence.”115 However, that requirement was removed in 2013 after the CMS determined that it did not improve health outcomes for Medicare beneficiaries. Although the 1991 NIH guidelines continue to be the most widely accepted standards for selecting patients for bariatric surgery,27 many experts have indicated a need to develop updated guidelines. This is because the criteria do not consider age; race or ethnicity; and, particularly for the lower BMI range, the severity of coexisting comorbidities.114 116

In 2007, a 50 member international, multidisciplinary Diabetes Surgery Summit Consensus Conference concluded that strictly BMI based criteria were inadequate for selecting candidates for diabetes surgery. It was proposed that Roux-en-Y gastric bypass surgery could be considered in carefully selected moderately obese patients (BMI 30-35) with type 2 diabetes who were inadequately controlled by conventional medical and behavioral therapies.117 Consensus was not reached on the use of adjustable gastric banding or other bariatric procedures for this lower BMI population. These recommendations were endorsed by 21 professional and scientific organizations.112 117 118 However, in 2009, the CMS determined that bariatric procedures in patients with type 2 diabetes and a BMI less than 35 were “not reasonable and necessary” and therefore not covered.115 Despite the CMS coverage decision, in 2011, the US Food and Drug Administration approved the use of laparoscopic adjustable gastric banding for adults with a BMI 30-35 and at least one obesity related health condition. The strength of the evidence base for the FDA’s decision has been questioned.119 Finally, in 2013, updated guidelines were released for the perioperative nutritional, metabolic, and non-surgical support of patients who have undergone bariatric surgery.112

Costs

The ability of bariatric surgery to reduce expenditures sufficiently to achieve cost savings continues to be debated.120 In two early observational studies, bariatric surgery seemed to be cost saving over a relatively short period of time.121 122 More recent observational studies,70 123 including an analysis of 29 820 Blue Cross Blue Shield Association enrollees, show no evidence of cost savings.124

In general, evidence suggests that outpatient costs, including pharmacy costs, are reduced after bariatric surgery. However, long term inpatient costs are increased or unchanged in patients who have undergone bariatric surgery compared with matched non-surgical patients, so no long term net cost benefit is seen. These results from observational cohorts are consistent with previous modeled cost effectiveness evaluations.19 20 125 Such evaluations have shown that bariatric procedures are likely to be cost effective, but not cost saving, compared with usual medical care or intensive lifestyle interventions for the average patient with severe obesity.

Shared decision making in the management of obesity

Given the considerable trade-offs between the risks, benefits, and uncertainties of the long term effects of bariatric procedures, the decision to undergo surgery should be based on a shared decision making process.126 127 The essential components of this process are clear communication of the clinician’s expert judgment, elicitation of the patient’s own values and preferences, and use of a patient decision aid that provides objective information about all clinically appropriate treatment options and encourages the patient to be meaningfully involved in decision making.128 One RCT showed that use of a video based patient decision aid for bariatric surgery led to greater improvements in patient knowledge, decisional conflict, and outcome expectancies than an educational booklet on bariatric surgery produced by the NIH.129

The shared decision making approach was endorsed at the 1991 NIH consensus conference on bariatric surgery.113 It recommended the following:

All patients should have an opportunity to explore with the physician any previously unconsidered treatment options and the advantages and disadvantages of each

The physician must fully discuss with the patient:

-The probable outcomes of the surgery

-The probable extent to which surgery will eliminate the patient’s problems

-The compliance that will be needed in the postoperative regimen

-The possible complications from the surgery, both short term and long term

The need for lifelong medical surveillance after surgery should be clear

With all of these considerations, the patient should be helped to arrive at a fully informed independent decision about his or her treatment.113

Looking ahead

Several important studies in the area of bariatric surgery are ongoing, including prospective and retrospective observational studies, and RCTs comparing contemporary procedures with non-surgical care of severely obese patients. The previously mentioned LABS-2 study will answer some questions about the comparative efficacy and safety of surgical procedures as well as the durability of weight loss and health improvements.130 Three year data were recently published, and seven year follow-up is planned.

A parallel Teen-LABS study will answer similar questions in adolescents with severe obesity undergoing bariatric surgery. Seven NIH funded RCTs of bariatric surgery are ongoing or have been recently completed, and at least 13 international RCTs are ongoing. In the next few years, these RCTs will probably provide more definitive answers to questions about the efficacy of bariatric procedures versus usual or intensive medical care or lifestyle interventions in the short term, especially for patients with type 2 diabetes and a BMI of 30.0-39.9. In addition, several of these RCTs are currently planning follow-up for five years or longer, so pooled longer term results will be available.

Ongoing observational studies, including the Utah Obesity Study, the Michigan Bariatric Surgery Collaborative, and cohorts in the Health Maintenance Organization Research Network and US Department of Veterans Affairs, are all likely to yield important information in the next five years on the comparative efficacy, safety, and costs of surgical and non-surgical care. They should also provide data on the durability of weight loss and health improvements, including the impact on incident microvascular disease and cancer.

Conclusion

High quality data from RCTs have clearly established that bariatric procedures are more effective than medical or lifestyle interventions for inducing weight loss and initial remission of type 2 diabetes, even in less obese patients with a BMI between 30.0 and 39.9.21 Although evidence from randomized trials does not go beyond two years, a few rigorous observational studies have shown encouraging results. These include an improvement in long term survival,17 18 a reduced risk of incident cardiovascular disease and diabetes,68 74 and more durable improvements in obesity related comorbidities among patients who have undergone bariatric surgery than among matched non-surgical controls.24 67

However, bariatric procedures are not without risks. The perioperative mortality for the average patient is low (<0.3%) and declining,90 but varies across subgroups, with perioperative mortality rates of 2.0% or higher in some patient populations.90 91 92 93 The incidence of complications after surgery varies from 4% to 25% and depends on the duration of follow-up, the definition of complication used, the type of bariatric procedure performed, and individual patient characteristics.15 26 91 94 95

Emerging data from observational studies also show that some procedures are associated with a greater long term risk of substance misuse disorders,103 104 105 suicide,106 and nutritional deficiencies.107 More research is needed to examine differences in long term outcomes across various procedures and heterogeneous patient populations, and to identify those who are most likely to benefit from surgical intervention. Given the persistent uncertainties about the long term trade-offs between the risks and benefits of bariatric surgery, the decision to undergo surgery should be based on a high quality shared decision making process.

What are the specific mechanisms of action responsible for weight loss and the type 2 diabetes response to bariatric surgical procedures?

What patient level factors can predict success (weight loss, health improvements, and cost savings) after bariatric surgical procedures?

Is bariatric surgery more effective than non-surgical care for the long term treatment of type 2 diabetes in people with less severe obesity (body mass index <35)?

On implementation of standardized reporting of complications across bariatric studies, what are the long term complication rates after different bariatric procedures?

What is the effect of bariatric surgery on long term microvascular and macrovascular event rates?